Literature DB >> 5410397

Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

F McDowell, J E Lee, T Swift, R D Sweet, J S Ogsbury, J T Kessler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5410397     DOI: 10.7326/0003-4819-72-1-29

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  34 in total

Review 1.  Parkinson's disease and levodopa. A five-year follow-up and review.

Authors:  C H Markham; L J Treciokas; S G Diamond
Journal:  West J Med       Date:  1974-09

2.  Treatment of Parkinson's Disease with levodopa and amantadine used as single drugs and in combined therapy.

Authors:  N Callagham; M Mcllroy; M O'Connor
Journal:  Ir J Med Sci       Date:  1974-03       Impact factor: 1.568

Review 3.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

4.  [Dopa resorption and dopamin estimation in blood of patients with Parkinson's disease (author's transl)].

Authors:  E Metzel; W U Weitbrecht
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974

5.  Certain prediction on the effectiveness of L-DOPA on parkinsonism.

Authors:  S Lavy; O Abramsky; A Carmon; I Yaar; S Feldman
Journal:  Z Neurol       Date:  1973-02-26

6.  Treatment of Parkinson's syndrome with L-DOPA on an out-patient basis.

Authors:  C Fehling
Journal:  Z Neurol       Date:  1972

7.  Levodopa's awakening effect on patients with Parkinsonism.

Authors:  G G Marsh; C M Markham; R Ansel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-06       Impact factor: 10.154

8.  Idiopathic orthostatic hypotension treated with levodopa and MAO inhibitor: a preliminary report.

Authors:  J Sharpe; A Marquez-Julio; P Ashby
Journal:  Can Med Assoc J       Date:  1972-08-19       Impact factor: 8.262

9.  An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.

Authors:  R J Mones
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-06       Impact factor: 10.154

10.  Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1971-07-10       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.